Trial Profile
Immunogenicity and tolerability of an AdVac-based tuberculosis vaccine in subjects previously vaccinated with BCG.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2010
Price :
$35
*
At a glance
- Drugs Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Crucell
- 18 Feb 2010 Results published in the American Journal of Respiratory and Critical Care Medicine.
- 09 Apr 2008 Preliminary results reported in an Aeras/Crucell/SATVI media release.
- 09 Apr 2008 Progress update and immunology data presented at the Tuberculosis Vaccines for the World conference.